Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study
Authors' conclusion
From 2003 to 2023, patients who were administered rocuronium plus sugammadex were at a significantly higher risk for acute cardiovascular and pulmonary complications when compared to patients who were administered cisatracurium plus neostigmine.
Study context
- Population
- Patients aged 18 to 80 years with chronic kidney disease (CKD), TriNetX network, 2003 to 2023propensity matched
- Participants
- 95,740 vs 10,708
- Exposure
- Rocuronium with sugammadex vs cisatracurium with neostigmine
- Cohort An = 95,740
- Cohort Bn = 10,708reference
- Outcome
- Acute complications
- Follow-up
- Same day to 1 week after administration
Methodological detailspropensity-matched, multicentre database (TriNetX, 63 health care organizations)
- Propensity-matched
- Multicentre database (TriNetX, 63 health care organizations)
Main finding
As reported in the abstract
same day to 1 week
Cohort A vs Cohort BRelative risk (CI)P value
Respiratory failure
1.98(1.71–2.29)
P < 0.0001Acute respiratory distress
2.70(1.31–5.58)
P = 0.0052Hypertensive crisis
1.85(1.37–2.49)
P < 0.0001HF
1.14(1.06–1.23)
P = 0.0004Pleural effusion
1.30(1.14–1.49)
P < 0.0001Observational data: associations, not effects.
Further findings
| Outcome | RR (CI) | P value | |
|---|---|---|---|
| Mortality · 30 days | 1.31 (1.10–1.56) | P = 0.0021 | |
| 0.512Relative risk (log scale) |
Original publication
Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study. Anesth Analg. Published 1 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →